Rheumatoid arthritis Trials in Meridian, United States
Conditions / Rheumatoid arthritis / Meridian, United States
Clinical trials for Rheumatoid arthritis investigate a range of treatment strategies and patient populations.
23 total trials for this combination
Showing top 10 of 23 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02097745 | A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies | COMPLETED | PHASE3 |
| NCT00476996 | A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT) | TERMINATED | PHASE3 |
| NCT00468546 | A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy | COMPLETED | PHASE3 |
| NCT01331837 | A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors | COMPLETED | PHASE4 |
| NCT00106522 | A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy | COMPLETED | PHASE3 |
| NCT02373813 | Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission | COMPLETED | PHASE3 |
| NCT00720798 | An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies | COMPLETED | PHASE3 |
| NCT02629159 | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT02706847 | A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs | COMPLETED | PHASE3 |
| NCT01709578 | To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET) | COMPLETED | PHASE3 |